2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMORecruiting
The overall objective is to perform simulations in a computer model of the human brain to map out the optimal parameters for non-invasive brain stimulation in AD. Simulations will be performed in both general and personalised models, the latter…